Stephen Bardin to Join atai Life Sciences as CFO Designate
atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”),
a clinical stage biopharmaceutical company aiming to transform the
treatment of mental health disorders, announced today that Stephen
Bardin, currently Senior Vice President of Finance and Operations
at BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio"), will be
appointed Chief Financial Officer during the third quarter of 2022.
Initially, Mr. Bardin will join the Company as Deputy CFO and
CFO Designate on June 27th and will be supported in his transition
by current CFO Greg Weaver. Mr. Weaver, after two years of
exceptional service to the Company, will subsequently step into a
strategic advisory role which is expected to conclude on March 31,
2023.
Mr. Bardin spent nearly three years at BridgeBio, a
commercial-stage biopharmaceutical company with a broad pipeline of
development programs, where he oversaw a broad range of finance
activities and helped raise over USD 2B through a variety of
financing transactions. Prior to that, Mr. Bardin held positions
focused on finance, operations and corporate development at Myovant
Sciences, Inc., Halo Neuroscience, Inc., and the Boston Consulting
Group. He holds an M.B.A. from the Stanford Graduate School of
Business and graduated summa cum laude from Duke University with a
B.S.E. in Biomedical Engineering.
“Stephen’s highly relevant experience and his unique insights
into our hub and spoke model of drug development make him the
perfect fit for our team. I am thrilled to have him join us on our
mission to pioneer the development of highly effective mental
health treatments,” said atai Co-Founder and CEO Florian Brand. “We
also extend our deepest gratitude to Greg for his achievements in
building a strong finance function and his leadership during our
successful IPO. We would not be where we are today without
him.”
“I am so proud of what we achieved as a team at atai during my
tenure over the last two years,” said Mr. Weaver. “With a cash
balance of USD 335M (as of March 31, 2022), we have built a company
that is very well capitalized and in a uniquely strong position for
success given its leadership and diverse pipeline of potentially
transformative mental health treatments. I have no doubt that
Stephen will be an excellent addition to atai’s leadership
team.”
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company
aiming to transform the treatment of mental health disorders.
Founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape, atai
is dedicated to acquiring, incubating, and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
atai's business model combines funding, technology, scientific,
and regulatory expertise with a focus on innovative compounds,
including psychedelic therapy and other drugs with differentiated
safety profiles and therapeutic potential. By pooling resources and
best practices, atai aims to responsibly accelerate the development
of new medicines across its companies to achieve clinically
meaningful and sustained behavioral change in mental health
patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “anticipate,” “initiate,”
“could,” “would,” “project,” “plan,” “potentially,” “preliminary,”
“likely,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. All statements contained in this
press release other than statements of historical fact, including
statements regarding our expectations relating to management
transition changes and related timelines, our future operating
results and financial position, our business strategy and plans,
and the plans and objectives of management for future operations
and capital expenditures, are forward-looking statements. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond our control and which could cause actual results, levels of
activity, performance or achievements to differ materially from
those expressed or implied by these forward-looking statements.
Other risk factors include the important factors described in
the section titled “Risk Factors” in our most recent Annual Report
on Form 10-K filed with the Securities and Exchange Commission
(“SEC”), as updated by our subsequent filings with the SEC, that
may cause our actual results, performance, or achievements to
differ materially and adversely from those expressed or implied by
the forward-looking statements.
Any forward-looking statements made herein speak only as of the
date of this press release, and you should not rely on
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, performance, or achievements reflected in the
forward-looking statements will be achieved or will occur. Except
as required by applicable law, we undertake no obligation to update
any of these forward-looking statements for any reason after the
date of this press release or to conform these statements to actual
results or revised expectations.
Investor Contact
Greg WeaverChief Financial OfficerGreg.Weaver@atai.life
Media Contact
Allan Malievsky, Senior Director, External Affairs
allan@atai.life
Grafico Azioni ATAI Life Sciences NV (TG:9VC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni ATAI Life Sciences NV (TG:9VC)
Storico
Da Apr 2023 a Apr 2024